From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

SkinBioTherapeutics – “finalisation of commercial agreement with Croda” to further spark the shares, Buy

By HotStockRockets | Saturday 23 November 2024


Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


SkinBioTherapeutics (SBTX) has announced, based on the final testing of its SkinBiotix technology, that it has finalised the commercial terms of an agreement with FTSE 100 speciality chemicals company Croda (CRDA). This is highly encouraging as it follows the results of additional studies which are described as “all very positive, and the product is now in the marketing and commercialisation phase” with a commercial team from Croda “which includes the launch of multimillion pound blockbuster products such as Matrixyl” (skin ingredient), whilst the current SkinBioTherapeutics market cap, at an up to 15.625p share price, is still just £35.7 million.
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

APH

Alliance Pharma – a recovery Buy?

 

PICH

Pitch Pit – this stinks

 

GEX

Georgina Energy: Lyin’ Yet again

Time left: 09:59:49